ESMO Open

Article	Citations
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆	194
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers	107
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)	105
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN	97
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update	87
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials	86
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?	77
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment	75
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era	75
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando	75
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies	74
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	69
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations	69
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	66
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment	65
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses	62
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis	59
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study	57
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines	55
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer	51
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application	49
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort	49
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France	48
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer	47
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis	46

How I treat biliary tract cancer	45
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration	44
Targeting immunoliposomes to EGFR-positive glioblastoma	43
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer	42
How to use liquid biopsies to treat patients with cancer	41
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge	38
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study	38
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment	38
Strategies to tackle RAS-mutated metastatic colorectal cancer	37
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	37
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical	37
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	36
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	36
How we treat primary central nervous system lymphoma	36
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts	35
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer	35
Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study	35
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort	34
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy	34
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	34
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring	34
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score	33
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer	33
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study	32
How we treat endocrine complications of immune checkpoint inhibitors	32
Consensus for HER2 alterations testing in non-small-cell lung cancer	32
Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up	31
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer	31
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape	31
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials	31
Impact of the COVID-19 pandemic on the care of cancer patients in Spain	31
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus	31
Supportive care in patients with cancer during the COVID-19 pandemic	30
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck	29
Immune checkpoint inhibitor administration during pregnancy: a case series	29
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer	29
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer	29
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies	27
Recurrent or primary metastatic cervical cancer: current and future treatments	27
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program	27
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆	27
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario	27
Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature	27
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review	27
Anti-TIGIT therapies for solid tumors: a systematic review	26
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up	26
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer	26
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients	26
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies	26
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903	26

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms	25
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States	25
Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials	25
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia	25
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 3	24
The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series	24
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival	24
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy	23
How we treat HER2-positive brain metastases	23
How we treat patients with metastatic HER2-positive breast cancer	23
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective	23
Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy	23
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial	23
Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer	23
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib	22
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis	22
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study	22
Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey	21
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database	21
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations	21
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncolog	21
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions	21
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study	20
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)	20
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer	20
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards	20
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials	20
Breast cancer in very young women—a multicenter 10-year experience	20
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort	20
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer	20
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	20
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study	20
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN	20
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey	19
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II	19
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival	19
Small-cell lung cancer in never-smokers	19
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer	19
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Canc	19
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis	19
Distribution of the workforce involved in cancer care: a systematic review of the literature	18
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	18
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer	18
Vaccination against Her-2/neu, with focus on peptide-based vaccines	18
Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer	18
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study	18
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery	17
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis	17
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials	17
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients	17
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy	17
Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies	17
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer	17
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review	17
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patient	16
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial	16
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)	16
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer	16
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center	16
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study	16
Sex and gender perspectives in colorectal cancer	16
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma	16
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer	16
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational coho	16
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors	16
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer	16
Role of molecular genetics in the clinical management of cholangiocarcinoma	16
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials	16
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours	16
Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma	16
Genomic profiling in non-small-cell lung cancer in young patients. A systematic review	16
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)	15
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy	15
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)	15
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients	15
How to read a next-generation sequencing report—what oncologists need to know	15
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022	15
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy	15
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)	15
Targeting KRASG12C in colorectal cancer: the beginning of a new era	15

Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery	15
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers	15
Emerging targets for anticancer vaccination: IDH	15
Emerging targets for anticancer vaccination: PD-1	15
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study	15
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆	15
Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit	14
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	14
Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’	14
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer	14
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer	14
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	14
Flexible care in breast cancer	14
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study	14
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network	14
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma	14
How I perform fertility preservation in breast cancer patients	14
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis	14
The DNA damage response network in the treatment of head and neck squamous cell carcinoma	14
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management	13
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-	13
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies	13
Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma	13
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial	13
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients	13
How I treat stage II colon cancer patients	13
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study	13
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalut	13
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an upda	13
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study	13
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study	12
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)	12
High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different soli	12
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101	12
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA	12
Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated wi	12
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer	12
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases	12
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern	12
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs	12
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials	12
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline	12
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors	12
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment	12
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients	12
The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study	12
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	12
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	12
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network	11
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?	11
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	11
ctDNA as a biomarker of progression in oesophageal adenocarcinoma	11
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study	11
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future	11
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma	11
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications	11
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey	11
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic r	11
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study	11
Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆	11
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology	11
Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials	11
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial	11
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study	11
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression	11
Cancer diagnosis in Catalonia (Spain) after two years of COVID-19 pandemic: an incomplete recovery	11
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network	11
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome	11
How we treat locoregional melanoma	11
Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and scre	11
Targeting HER3 for cancer treatment: a new horizon for an old target	10
How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors	10
The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer	10
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type	10
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study	10
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis	10
Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)	10
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	10
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy	10
Cancer burden in adolescents and young adults in Europe	10
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial	10
Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis	10
The current role of precision surgery in oligometastatic prostate cancer	10
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians	10
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database	10
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7	10
Multimodal survival prediction in advanced pancreatic cancer using machine learning	10
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)	10
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial	10
Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers	10
Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis	10
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study	10
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer	10
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer	9
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)	9